Skip to content

Agios Pharmaceuticals, Inc.

AGIO· NasdaqCore metricsCIK 1439222

Pharmaceutical preparations552 peers

Last sale
Oct 1, 2026 · -2.45%
Market cap
$1.94B
59.78M shares
Filings
1,028
$55.39M
Q3 2026+48.0% FY25 yoy
-$65.05M
Q3 2026N/M FY25 yoy
-$77.16M
Q3 2026N/M FY25 yoy
-$238.64M
Q3 2026derivedN/M FY25 yoy
-$1.09
Q3 2026N/M FY25 yoy
$128.55M
Q3 2026+16.9% FY25 yoy
$1.94B
—
13.8×
2.0×
-17.32%
—

Twelve months to Sep 30, 2026 · derived

Price

$32.4519.17%$7.70past year
Oct 1, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$54.03MFY 2025
$117.91M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$54,028,000reported
FY 20242024-12-31$36,498,000reported
FY 20232023-12-31$26,823,000reported
FY 20222022-12-31$14,240,000reported
FY 20212021-12-31$0reported
FY 20202020-12-31$0 revisedreported
FY 20192019-12-31$117,912,000reported
FY 20182018-12-31$94,387,000reported
FY 20172017-12-31$43,011,000reported
FY 20162016-12-31$69,892,000reported
FY 20152015-12-31$59,119,000reported
FY 20142014-12-31$65,358,000reported

Capital returns

Dividends and buybacks · FY2019 to FY2023
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2023—$0.00$0.00—56.19M sh+1.6%—
FY2022—$0.00$0.00—55.29M sh+1.2%—
FY2021—$802.49M$802.49M—54.64M sh−21.5%—
FY2020—$0.00$0.00—69.60M sh+1.6%—
FY2019—$0.00$0.00—68.51M sh+17.3%—

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Product revenue, net · FY2018 · $13.84MCollaboration revenue – other · FY2018 · $12.67MCommercialization Activities · FY2018 · $3.74MDevelopment activities · FY2018 · $1.34MLicenses · FY2018 · $15.00MMilestone revenue · FY2018 · $7.22MOn-going research and development services · FY2018 · $40.58MFY2019Product revenue, net · FY2019 · $59.85MCollaboration revenue – other · FY2019 · $8.26MCommercialization Activities · FY2019 · $3.30MMilestone revenue · FY2019 · $10.54MOn-going research and development services · FY2019 · $35.95MFY2020Collaboration revenue – other · FY2020 · $3.57MCommercialization Activities · FY2020 · $3.93MOn-going research and development services · FY2020 · $64.35MFY2021FY2022Product revenue, net · FY2022 · $11.74MMilestone revenue · FY2022 · $2.50MFY2023Product revenue, net · FY2023 · $26.82MFY2024Product revenue, net · FY2024 · $36.50MFY2025Product revenue, net · FY2025 · $54.03M
LineFY2025ShareChange
Product revenue, net$54.03M100%+48.0%
Collaboration revenue – other———
Commercialization Activities———
Committee participation———
Development activities———
Licenses———
Milestone revenue———
On-going research and development services———
Total$54.03M

From the 10-K filed Feb 12, 2026AGIO

Pharmaceutical preparations

Agios Pharmaceuticals, Inc. is the 125th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR